PTC Therapeutics (FRA:BH3) Cyclically Adjusted FCF per Share: €-2.58 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €68.14
GF Value €31.76
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Cyclically Adjusted FCF per Share?

PTC Therapeutics FRA:BH3 +0.53% 51 Cyclically Adjusted FCF per Share is €-2.58 as of Mar. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €31.76. The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PTC Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.633. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.58 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of PTC Therapeutics was 11.80% per year. The lowest was -1.50% per year. And the median was 5.15% per year.

As of today (2026-07-22), PTC Therapeutics's current stock price is €68.14. PTC Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.58. PTC Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


PTC Therapeutics  (FRA:BH3) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PTC Therapeutics Cyclically Adjusted FCF per Share Related Terms


PTC Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Cyclically Adjusted FCF per Share Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.43 -4.12 -3.66 -3.83 -2.67

PTC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.52 -2.66 -2.67 -2.58

FRA:BH3 vs SRRK, COGT, RYTM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PTC Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.633/330.2130*330.2130
=-0.633

Current CPI (Mar. 2026) = 330.2130.

PTC Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.644 241.018 -0.882
201609 -0.636 241.428 -0.870
201612 -0.404 241.432 -0.553
201703 -0.794 243.801 -1.075
201706 0.291 244.955 0.392
201709 -1.898 246.819 -2.539
201712 0.393 246.524 0.526
201803 -0.319 249.554 -0.422
201806 -0.013 251.989 -0.017
201809 -0.033 252.439 -0.043
201812 -0.424 251.233 -0.557
201903 -0.717 254.202 -0.931
201906 -0.704 256.143 -0.908
201909 -0.451 256.759 -0.580
201912 -0.381 256.974 -0.490
202003 -1.436 258.115 -1.837
202006 -0.926 257.797 -1.186
202009 0.002 260.280 0.003
202012 -0.993 260.474 -1.259
202103 -1.436 264.877 -1.790
202106 -0.551 271.696 -0.670
202109 -0.927 274.310 -1.116
202112 -1.163 278.802 -1.377
202203 -2.280 287.504 -2.619
202206 -0.971 296.311 -1.082
202209 -0.903 296.808 -1.005
202212 -2.507 296.797 -2.789
202303 -0.927 301.836 -1.014
202306 -0.413 305.109 -0.447
202309 -0.544 307.789 -0.584
202312 -1.564 306.746 -1.684
202403 0.077 312.332 0.081
202406 -0.776 314.175 -0.816
202409 -1.028 315.301 -1.077
202412 -0.451 315.605 -0.472
202503 9.290 319.799 9.593
202506 -0.691 322.561 -0.707
202509 -3.154 324.800 -3.207
202512 -0.660 324.054 -0.673
202603 -0.633 330.213 -0.633

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.58 mean?
PTC Therapeutics (FRA:BH3) has a Cyclically Adjusted FCF per Share of €-2.58 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Cyclically Adjusted FCF per Share too high?
PTC Therapeutics' current Cyclically Adjusted FCF per Share is €-2.58. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Cyclically Adjusted FCF per Share compare to SRRK and COGT?
PTC Therapeutics' Cyclically Adjusted FCF per Share of €-2.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Cyclically Adjusted FCF per Share is €-2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Cyclically Adjusted FCF per Share of €-2.58. The stock's GF Value™ is €31.76, compared to a current price of €68.14 — trading 114.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.58. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Cyclically Adjusted FCF per Share is €-2.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €68.14 is trading 114.5% above its estimated GF Value™ of €31.76.

Key valuation signals for FRA:BH3:

  • Cyclically Adjusted FCF per Share: €-2.58
  • GF Value™: €31.76 vs. price of €68.14 (114.5% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.14
Price
€31.76
GF Value